摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-苄基-4-(2-氯喹啉-3-基)哌啶-4-醇 | 783368-13-8

中文名称
1-苄基-4-(2-氯喹啉-3-基)哌啶-4-醇
中文别名
3-(1-苄基-4-羟基哌啶-4-基)-2-氯喹啉
英文名称
3-(1-benzyl-4-hydroxypiperidin-4-yl)-2-chloroquinoline
英文别名
1-benzyl-4-(2-chloro-quinolin-3-yl)-piperidin-4-ol;1-Benzyl-4-(2-chloroquinolin-3-yl)piperidin-4-ol
1-苄基-4-(2-氯喹啉-3-基)哌啶-4-醇化学式
CAS
783368-13-8
化学式
C21H21ClN2O
mdl
——
分子量
352.864
InChiKey
ACOQCRWPQYUNSU-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    539.7±50.0 °C(Predicted)
  • 密度:
    1.284±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    4.1
  • 重原子数:
    25
  • 可旋转键数:
    3
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.29
  • 拓扑面积:
    36.4
  • 氢给体数:
    1
  • 氢受体数:
    3

SDS

SDS:53204ecfb99e773089d14929edf92296
查看

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    1-苄基-4-(2-氯喹啉-3-基)哌啶-4-醇盐酸potassium carbonate 作用下, 以 为溶剂, 反应 8.0h, 以45%的产率得到3-(1-苄基-3,6-二氢-2H-吡啶-4-基)-1H-喹啉-2-酮
    参考文献:
    名称:
    NOVEL COMPOUNDS
    摘要:
    本发明涉及一般式I的新CGRP拮抗剂,其中U、V、X、Y、R1、R2、R3和R4如描述中所述定义,其互变异构体、异构体、顺反异构体、对映异构体、水合物、混合物及其盐,以及其盐的水合物,特别是与无机或有机酸或碱形成的生理上可接受的盐,包含这些化合物的药物、其用途以及其制备方法。
    公开号:
    US20110195954A1
  • 作为产物:
    描述:
    N-苄基哌啶酮正丁基锂二乙胺 作用下, 以 四氢呋喃正己烷 为溶剂, 反应 2.67h, 生成 1-苄基-4-(2-氯喹啉-3-基)哌啶-4-醇
    参考文献:
    名称:
    WO2007/16087
    摘要:
    公开号:
点击查看最新优质反应信息

文献信息

  • CGRP receptor antagonists
    申请人:Gutierrez Corey
    公开号:US20080004261A1
    公开(公告)日:2008-01-03
    The present invention relates to CGRP receptor antagonists, pharmaceutical compositions thereof, and methods therewith for treating CGRP receptor-mediated diseases and conditions.
    本发明涉及CGRP受体拮抗剂,其药物组成物,以及用于治疗CGRP受体介导的疾病和症状的方法。
  • Benzodiazepine cgrp receptor antagonists
    申请人:Burgey S. Christopher
    公开号:US20060148790A1
    公开(公告)日:2006-07-06
    The present invention is directed to compounds of Formula I: (where variables R 1 , R 2 , R 3 , R 6 , R 7 , G, J, W, X and Y are as defined herein) useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.
    本发明涉及化合物I的公式:(其中变量R1,R2,R3,R6,R7,G,J,W,X和Y的定义如本文所述),用作CGRP受体拮抗剂,并用于治疗或预防CGRP参与的疾病,例如头痛,偏头痛和群头痛。本发明还涉及包含这些化合物的制药组合物以及在预防或治疗CGRP参与的这些疾病中使用这些化合物和组合物的用途。
  • Cgrp receptor antagonists
    申请人:Burgey S. Christopher
    公开号:US20060194783A1
    公开(公告)日:2006-08-31
    The present invention is directed to compounds of Formula I and Formula II: (where variables R1, R2, R3, R4, R6, A, B, G, J, W, X and Y are as defined herein) useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.
    本发明涉及式I和式II的化合物:(其中变量R1、R2、R3、R4、R6、A、B、G、J、W、X和Y如本文所定义),其作为CGRP受体拮抗剂在治疗或预防涉及CGRP的疾病,例如头痛、偏头痛和群发性头痛中有用。本发明还涉及包含这些化合物的制药组合物以及在预防或治疗涉及CGRP的这些疾病中使用这些化合物和组合物的用途。
  • Cgrp Receptor Antagonists
    申请人:Paone Daniel V.
    公开号:US20080261972A1
    公开(公告)日:2008-10-23
    Compounds of Formula (I), (where variables R 1 , A, B, W, X, Y and Z are as defined herein) useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.
    式(I)的化合物(其中变量R1、A、B、W、X、Y和Z如本文所定义),可用作CGRP受体的拮抗剂,并可用于治疗或预防CGRP参与的疾病,如头痛、偏头痛和集群头痛。本发明还涉及包含这些化合物的制药组合物以及使用这些化合物和组合物预防或治疗CGRP参与的这些疾病的方法。
  • Benzodiazepine CGRP receptor antagonists
    申请人:Merck & Co, Inc.
    公开号:US07196079B2
    公开(公告)日:2007-03-27
    The present invention is directed to compounds of Formula I: (where variables R1, R2, R3, R6, R7, G, J, W, X and Y are as defined herein) useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.
    本发明涉及一种化合物,其化学式为I:(其中变量R1、R2、R3、R6、R7、G、J、W、X和Y如本文所定义),该化合物可用作CGRP受体的拮抗剂,可用于治疗或预防CGRP参与的疾病,如头痛、偏头痛和丛集性头痛。本发明还涉及包含这些化合物的制药组合物以及这些化合物和组合物在预防或治疗CGRP参与的这些疾病中的应用。
查看更多